Showing results (1-10 of 279) with videos related to

Sort By:
Pageof 28
Der Urologe. Ausg. A|May 20, 2006
[Metastases with CUP syndrome]S Seeber, D Strumberg
Anti-Cancer Drugs|June 23, 1998
Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I studyU Klaassen, A Harstrick, D Strumberg, et al.
Anti-Cancer Drugs|June 1, 1996
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell linesD Strumberg, A Harstrick, K Doll, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancerU Klaassen, H Wilke, D Strumberg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinomaD Strumberg, J Erhard, A Harstrick, et al.
Anti-Cancer Drugs|March 1, 1997
Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracilD Strumberg, A Harstrick, U Klaassen, et al.
Leukemia|May 1, 1994
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinosideM Flasshove, D Strumberg, L Ayscue, et al.
Seminars in Oncology|December 1, 1995
Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysisU Klaassen, H Wilke, C P Pari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinomaA Harstrick, C H Köhne, W Hiddemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II studyU Klaassen, H Wilke, A Harstrick, et al.
Pageof 28